Frequently Asked Questions

Mix both: 2′‑F increases A‑form bias and T_m; 2′‑OMe is helpful for safety and reduces off‑targeting, especially in the seed region.

It can. Lipids may introduce steric effects, hydrophobic aggregation or altered duplex behavior. PEG or TEG spacers are often used to preserve hybridization and reduce self-association.

Use cleavable (disulfide, hydrazone, dipeptide/self‑immolative) when intracellular release is needed; choose non‑cleavable when maximal durability is required.

Use dark quenchers with tight spectral separation and verify droplet reader channels. Pilot dye-quencher combinations under final reaction conditions.

 Many designs can combine 2′→5′ linkages with fluorescent labels, quenchers, biotin, amino modifiers, thiol modifiers, click handles or spacers, but compatibility should be reviewed during design.

No. 2′-AmNA is an amido-bridged, conformationally constrained nucleic acid, whereas 2′-O-NMA is a distinct non-bridged 2′ sugar modification. They should be specified separately.

 PCR compatibility depends on modification placement, primer design, polymerase tolerance, and the intended amplification strategy. Modified oligos should be experimentally validated in the target PCR system before routine use.

Yes. Research-grade acetylated peptides are typically chemically synthesized so acetylation is installed at defined residue positions and stoichiometry. Synthetic acetylated peptides avoid heterogeneity and are preferred for mechanistic studies, quantitative LC–MS workflows, and assay controls.

 Yes. Depending on the sequence, modification and application, purification may include desalting, HPLC, PAGE or other fit-for-purpose workflows with analytical QC documentation.

No. Many reactive, bulky, light-sensitive, or unstable groups are better introduced after cleavage. The library identifies a typical route, but sequence-specific review is required.

No. Hybridization with natural nucleic acids depends on scaffold geometry, stereochemistry and sequence. Some XNAs pair strongly with DNA or RNA, while others primarily form stable self-paired duplexes.

Toxicity depends on sequence, chemistry, delivery method, and concentration. PS-ASOs may bind non-specifically to proteins and activate immune receptors.

Often yes. The extra constraints can reduce protease-sensitive conformations and improve structural persistence, though final stability depends on sequence, bridge chemistry, and assay environment.

No. Lysine-based MAP peptides are common, but branched peptides can also be designed using alternative diamino acid branch points (Dap/Dab/Orn), dendrimeric or small-molecule cores, and post-synthetic branching chemistries (e.g., cysteine/thioether or click chemistry). The best strategy depends on the required spacing/geometry, steric congestion risk, solubility, stability, and your downstream application.

Yes. CPPs are peptides (not small molecules), but they are widely grouped under delivery modifiers because they enhance cellular uptake and intracellular trafficking. CPP–oligo conjugates are common for splice-switching oligos (SSO), PMO, and peptide–PMO programs.

Yes. Synthetic citrullinated peptides are frequently used for method development, site confirmation, retention studies, and quantitative workflows.

Cleavable linker concepts (e.g., enzyme-, pH-, or redox-responsive) can be evaluated when controlled payload release is desired. Linker selection is guided by the oncology drug, peptide sequence, and intended biological environment.

Yes. Cyclization is a major structural-engineering strategy because covalent closure directly constrains peptide conformation and may protect the termini.

Yes. Dendrimers are dendritic polymer architectures with highly branched, tree-like structures and many terminal functional groups.

 Yes. Deuterated oligos are well suited for isotope-dilution LC-MS methods because they provide a defined mass offset while preserving the parent oligonucleotide sequence.